Eric Assénat
机构：Institut de Recherche en Cancérologie de Montpellier · ORCID：0000-0002-8958-2793
发表论文 330 篇 · 总被引 23412 次 · h-index 53
代表论文
- Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study (2025 · The Lancet · 被引 270)
- Absorbed Dose–Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [ 177 Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine (2024 · Journal of Nuclear Medicine · 被引 59)
- Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma (2024 · Annals of Oncology · 被引 37)
- Management of hepatocellular carcinoma recurrence after liver surgery and thermal ablations: state of the art and future perspectives (2024 · HepatoBiliary Surgery and Nutrition · 被引 35)
- Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PRODIGE48 study) (2025 · Journal of Clinical Oncology · 被引 24)
- Impact of Lean Body Mass–Based Oxaliplatin Dose Calculation on Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer: Results of the Phase II Randomized LEANOX Trial (2025 · Journal of Clinical Oncology · 被引 16)